Literature DB >> 23686009

Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model.

Xinhui Wang1, Guoqing Gong2, Wenhui Yang1, Yunzhan Li1, Meiling Jiang1, Linlin Li1.   

Abstract

This study aimed to investigate the effects of galangin on liver fibrosis in rats induced by subcutaneous injection of carbon tetrachloride (CCl4). The administration of CCl4 to rats for 12 weeks caused significant increase of hyaluronic acid, laminin, alanine transaminase, aspartate transaminase and decrease of total protein, albumin in serum, while the influences could be reversed by galangin. Galangin markedly reduced hepatic malondialdehyde, hydroxyproline concentration, increased activities of liver superoxide dismutase, glutathione peroxidase compared with CCl4-treated rats. Histological results indicated that galangin alleviated liver damage. In addition, treatment with galangin significantly down-regulated expressions of α-smooth muscle actin and transforming growth factor β1. These results suggest galangin can inhibit liver fibrosis induced by CCl4 in rats, which was probably associated with its effect on removing oxygen free radicals, decreasing lipid peroxidation, as well as inhibiting hepatic stellate cells activation and proliferation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALB; ALT; AST; CCl(4); CMC-Na; ECM; GSH-Px; HA; HI; HSCs; Hyp; LN; MDA; ROS; SOD; TGF-β1; TP; alanine transaminase; albumin; aspartate transaminase; carbon tetrachloride; carboxymethyl cellulose-Na; extracellular matrix; glutathione peroxidase; hepatic index; hepatic stellate cells; hyaluronic acid; hydroxyproline; laminin; malondialdehyde; reactive oxygen species; superoxide dismutase; total protein; transforming growth factor β1; α-SMA; α-smooth muscle actin

Mesh:

Substances:

Year:  2013        PMID: 23686009     DOI: 10.1016/j.etap.2013.04.004

Source DB:  PubMed          Journal:  Environ Toxicol Pharmacol        ISSN: 1382-6689            Impact factor:   4.860


  23 in total

1.  Galangin inhibits hypertrophic scar formation via ALK5/Smad2/3 signaling pathway.

Authors:  Yifan Zhang; Shengzhou Shan; Jing Wang; Xinyu Cheng; Bo Yi; Jia Zhou; Qingfeng Li
Journal:  Mol Cell Biochem       Date:  2016-01-04       Impact factor: 3.396

2.  Anti-neuroinflammatory effects of galangin in LPS-stimulated BV-2 microglia through regulation of IL-1β production and the NF-κB signaling pathways.

Authors:  Mi Eun Kim; Pu Reum Park; Ju Yong Na; Inae Jung; Jun Hwi Cho; Jun Sik Lee
Journal:  Mol Cell Biochem       Date:  2018-07-11       Impact factor: 3.396

3.  Protective effect of galangin in Concanavalin A-induced hepatitis in mice.

Authors:  Qingqiong Luo; Liping Zhu; Jieying Ding; Xing Zhuang; Lili Xu; Fuxiang Chen
Journal:  Drug Des Devel Ther       Date:  2015-06-10       Impact factor: 4.162

4.  Sequencing, De novo Assembly, Functional Annotation and Analysis of Phyllanthus amarus Leaf Transcriptome Using the Illumina Platform.

Authors:  Aparupa Bose Mazumdar; Sharmila Chattopadhyay
Journal:  Front Plant Sci       Date:  2016-01-28       Impact factor: 5.753

5.  Activation of the JNK-c-Jun pathway in response to irradiation facilitates Fas ligand secretion in hepatoma cells and increases hepatocyte injury.

Authors:  Yinying Dong; Xiaoyun Shen; Mingyan He; Zhifeng Wu; Qiongdan Zheng; Yaohui Wang; Yuhan Chen; Sifan Wu; Jiefeng Cui; Zhaochong Zeng
Journal:  J Exp Clin Cancer Res       Date:  2016-07-18

6.  Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.

Authors:  Gianni Paulis; Andrea Paulis; Gennaro Romano; Davide Barletta; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2017-07-20

Review 7.  Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review.

Authors:  Gianni Paulis; Gennaro Romano; Luca Paulis; Davide Barletta
Journal:  Adv Urol       Date:  2017-07-04

8.  Application of galangin, an active component of Alpinia officinarum Hance (Zingiberaceae), for use in drug-eluting stents.

Authors:  Jung-Jin Lee; Ji-Hye Lee; Nam-Hui Yim; Joo-Hui Han; Jin Yeul Ma
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

9.  Galangin Resolves Cardiometabolic Disorders through Modulation of AdipoR1, COX-2, and NF-κB Expression in Rats Fed a High-Fat Diet.

Authors:  Patoomporn Prasatthong; Sariya Meephat; Siwayu Rattanakanokchai; Juthamas Khamseekaew; Sarawoot Bunbupha; Parichat Prachaney; Putcharawipa Maneesai; Poungrat Pakdeechote
Journal:  Antioxidants (Basel)       Date:  2021-05-12

10.  Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma.

Authors:  Ya-Nan Liu; Wang-Jian Zha; Yuan Ma; Fei-Fei Chen; Wen Zhu; Ai Ge; Xiao-Ning Zeng; Mao Huang
Journal:  Sci Rep       Date:  2015-07-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.